GlassScriptPhysician profile
Jodi Straube
NPI 1255903209
$26,413.93
in general payments reported to CMS, 2019-2025
16 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $403 · 2023: $3,084 · 2024: $4,788 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Honoraria: $10K · Consulting Fee: $1,735 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,525 · Travel and Lodging: $1,377 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,078.41 |
| Honoraria | $10,250.00 |
| Consulting Fee | $1,735.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,525.00 |
| Travel and Lodging | $1,377.09 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $12,729.95 | 2025 | Symbravo |
| Abbvie INC. | $5,913.05 | 2022-2025 | |
| Pfizer INC. | $3,376.19 | 2023-2025 | |
| Lundbeck LLC | $2,037.53 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $973.96 | 2022-2025 | Ajovy |
| Lilly USA, LLC | $347.64 | 2022-2024 | Emgality, Reyvow |
| Upsher-Smith Laboratories LLC | $222.44 | 2022-2023 | |
| Tonix Medicines, INC. | $193.69 | 2024-2025 | Zembrace Symtouch |
| Impel Pharmaceuticals INC. | $164.52 | 2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $152.33 | 2022 | |
| Impel Pharmaceuticals LLC | $98.40 | 2024-2025 | Trudhesa |
| Amgen INC. | $91.76 | 2022-2023 | Aimovig |
| Scilex Pharmaceuticals INC. | $45.15 | 2024 | |
| Glaxosmithkline, LLC. | $27.96 | 2022 | |
| Amneal Pharmaceuticals LLC | $22.04 | 2025 | Brekiya |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $17.32 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Straube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.